US 2025/0051449 A1Published application

Anti-CD112R Compositions and Methods

AssigneeSurface Oncology, Inc.

InventorsBianka PRINZ, Nadthakarn BOLAND, Kevin SCHUTZ, John BUKOWSKI, Jennifer SYMONDS, James MOHAN, Marisella Panduro SICHEVA

Life of this patent

Estimating the term…

Abstract

The invention provides anti-CD112R antibody compositions and their use in treating cancer.

Claims41

Dependent claims

An isolated antibody comprising:

i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
1;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
2;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
3;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
4;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
5;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
6;
or
ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
101;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
102;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
103;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
104;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
105;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
106;
or
iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
201;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
202;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
203;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
204;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
205;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
206;
or
iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
301;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
302;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
303;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
304;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
305;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
306;
or
v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
401;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
402;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
403;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
404;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
405;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
406;
or
vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
501;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
502;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
503;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
504;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
505;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
506;
or
vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
601;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
602;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
603;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
604;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
605;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
606;
or
viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
701;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
702;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
703;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
704;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
705;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
706;
or
ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
801;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
802;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
803;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
804;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
805;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
806;
or
x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
901;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
902;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
903;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
904;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
905;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
906;
or
xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
1001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
1002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
1003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
1004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
1005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
1006;
or
xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
2001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
2002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
2003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
2004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
2005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
2006;
or
xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
3001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
3002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
3003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
3004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
3005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
3006;
or
xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
4001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
4002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
4003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
4004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
4005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
4006.

178 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/930,273Filed 29 Oct 2024
Priority: 20 Jul 2018
Published: 13 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 31/7088
Carbohydrates; Sugars; Derivatives thereof: compounds having three or more nucleosides or nucleotides
A61P 35/00
Antineoplastic agents
A61P 37/04
Immunomodulators: immunostimulants

Family

Application62/701,065Us provisional application · filed 20 Jul 2018
Application62/844,958Us provisional application · filed 8 May 2019
Application17/261,463Continuation · filed 19 Jan 2021
Application17/531,380Continuation · filed 19 Nov 2021
Application18/930,273Continuation
US 11,214,619 B2Related patent
US 12,162,941 B2Related patent
US 2021/0253699 A1Published application
US 2022/0162317 A1Published application
US 2025/0051449 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

An isolated antibody comprising:

i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
1;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
2;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
3;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
4;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
5;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
6;
or
ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
101;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
102;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
103;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
104;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
105;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
106;
or
iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
201;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
202;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
203;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
204;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
205;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
206;
or
iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
301;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
302;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
303;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
304;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
305;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
306;
or
v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
401;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
402;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
403;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
404;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
405;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
406;
or
vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
501;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
502;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
503;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
504;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
505;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
506;
or
vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
601;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
602;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
603;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
604;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
605;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
606;
or
viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
701;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
702;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
703;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
704;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
705;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
706;
or
ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
801;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
802;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
803;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
804;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
805;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
806;
or
x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
901;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
902;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
903;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
904;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
905;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
906;
or
xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
1001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
1002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
1003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
1004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
1005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
1006;
or
xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
2001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
2002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
2003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
2004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
2005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
2006;
or
xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
3001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
3002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
3003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
3004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
3005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
3006;
or
xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
4001;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
4002;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
4003;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
4004;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
4005;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
4006.

178 more elements

Facts

Application

18/930,273Filed 29 Oct 2024

Priority

20 Jul 2018

Published

13 Feb 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 31/7088
Carbohydrates; Sugars; Derivatives thereof: compounds having three or more nucleosides or nucleotides
A61P 35/00
Antineoplastic agents
A61P 37/04
Immunomodulators: immunostimulants

Family

Application62/701,065Us provisional application · filed 20 Jul 2018

Application62/844,958Us provisional application · filed 8 May 2019

Application17/261,463Continuation · filed 19 Jan 2021

Application17/531,380Continuation · filed 19 Nov 2021

Application18/930,273Continuation

US 11,214,619 B2Related patent

US 12,162,941 B2Related patent

US 2021/0253699 A1Published application

US 2022/0162317 A1Published application

US 2025/0051449 A1This patent

From the US filing history. Foreign family members aren’t listed.